Related Experiment Video
Updated: Oct 13, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Management of hepatitis B and C in special population
Anand V Kulkarni1, Nageshwar Reddy Duvvuru2
1Department of Hepatology, Asian Institute of Gastroenterology, Hyderabad 500032, Telangana, India. anandvk90@gmail.com.
Insights
New oral antiviral therapies offer effective treatment for chronic hepatitis B (CHB) and chronic hepatitis C (CHC). This review examines their use in special populations, including those with kidney disease and pregnant women.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic viral hepatitis B and C are major global causes of cirrhosis.
- Hepatitis B is prevalent in the Asia-Pacific, while Hepatitis C is more common in the West.
- Recent advancements include oral direct-acting antivirals (DAAs) for CHC and nucleos(t)ide analogs (NUCs) for CHB.
Purpose of the Study:
- To review the management of chronic hepatitis B and C in special patient populations.
- To discuss the evolving safety and efficacy data of oral antiviral therapies in these groups.
Main Methods:
- Literature review of current clinical guidelines and research.
- Analysis of treatment outcomes and safety profiles in specific populations.
Main Results:
- Oral DAAs and NUCs demonstrate high efficacy, good tolerability, and low resistance rates.
- Robust data is lacking for certain special populations, requiring ongoing research.
Conclusions:
- Oral antiviral therapies have revolutionized CHB and CHC management.
- Further investigation is needed to optimize treatment strategies for special populations, including those with chronic kidney disease, pregnant women, healthcare workers, and immunocompromised individuals.
Abstract:
Chronic viral hepatitis is one of the leading causes of cirrhosis worldwide. Chronic hepatitis B is more common in the Asia-Pacific region due to the larger population and lower screening availability. Hepatitis C predominates in the west due to injection drug abuse. The discovery of (oral) direct-acting antiviral agents (DAAs) has changed the landscape of chronic hepatitis C (CHC) management. Nucleos(t)ide analogs (NUCs) have also changed the approach to the treatment of chronic hepatitis B (CHB). Oral NUCs and DAAs have excellent efficacy and patient acceptance as well as a lower risk of resistance. However, certain populations have no robust data and safety and efficacy of such oral drugs is still evolving. In this review, we provide an overview of the management of CHB and CHC in special populations, such as those with chronic kidney disease, pregnant women, healthcare workers, and those undergoing chemo- or immunosuppressive therapy.
More Related Videos
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
10:25"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
Published on: February 19, 2019
Related Concept Videos
Standard Precaution
Hand hygiene is the most crucial means to prevent the transmission of disease. Employers are legally required to provide their workers with personal protective equipment (PPE) to minimize exposure or contact with...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Transmission-based Precautions I: Contact, Enteric, and Droplets
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...